PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis

Citation
Mestre, L., Redondo, M., Carrillo‐Salinas, F. J., Morales‐García, J. A., Alonso‐Gil, S., Pérez‐Castillo, A., Gil, C., Martínez, A., & Guaza, C. (2015). <scp>PDE</scp>7 inhibitor <scp>TC</scp>3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis. British Journal of Pharmacology, 172(17), 4277–4290. Portico. https://doi.org/10.1111/bph.13192
DOI:
DOI: 10.1111/bph.13192
Year of publication:
2015